Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses

By sjmartinez • November 16, 2022

Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser CB, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 Nov 15:e163471. doi: 10.1172/jci.insight.163471. Epub ahead of print. PMID: 36378539.

Tags: Adaptive immunity, covid-19, Immunology, Infectious Diseases, Publications

Coronavirus disease 2019 (COVID-19) infection prevention practices that exceed Centers for Disease Control and Prevention (CDC) guidance: Balancing extra caution against impediments to care

Gohil SK, Septimus E, Sands KE, Blanchard EJ, Moody J, de St Maurice A, Yokoe D, Kwon J, Grein J, Cohen S, Uslan D, Vasudev ...

Novel Host Pathways Govern Epithelial Cell Invasion of Aspergillus fumigatus

Liu H, Shetty AC, Ibrahim AS, Filler SG, Bruno VM. Novel Host Pathways Govern Epithelial Cell Invasion of Aspergillus fumigatus. Microbiol Spectr. 2023 May 31:e0008423. ...

Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial

Baksh SN, Heath SL, Fukuta Y, Shade D, Meisenberg B, Bloch EM, Tobian AAR, Spivak ES, Patel B, Gerber J, Raval JS, Forthal D, Paxton ...